Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 139, 2019 - Issue 2
Submit an article Journal homepage
298
Views
6
CrossRef citations to date
0
Altmetric
Articles

Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients

Hiroki SatoDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
,
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan; Correspondence[email protected]
,
Isaku OkamotoDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
,
Yasuaki KatsubeDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
,
Akira ShimizuDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
,
Takahito KondoDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan;
,
Kenji HanyuDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan;
,
Chihiro FushimiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan
,
Takuro OkadaDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan
&
Kouki MiuraDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan
 show all
Pages 201-205 | Received 12 Oct 2018, Accepted 18 Nov 2018, Published online: 22 Feb 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Background: Combination therapy consisting of a platinum agent, 5-fluorouracil and cetuximab (EXTREME regimen) is recommended for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). However, it is advisable to use platinum-free regimens as first-line therapy in patients resistant to platinum agents. There has been no report comparing EXTREME regimen outcomes between platinum-resistant and platinum-sensitive patients.

Objectives: We conducted this study to examine the outcomes of the EXTREME regimen as first-line therapy in patients with R/M-SCCHN and a history of platinum agent use and assess whether the EXTREME regimen outcomes differ between platinum-resistant and platinum-sensitive patients.

Materials and methods: The study included 32 patients with R/M-SCCHN who received the EXTREME regimen as first-line therapy. Patients with recurrence or metastasis within 6 months after cisplatin administration were considered platinum-resistant and those with no recurrence or metastasis within 6 months were considered platinum-sensitive.

Results: 17 patients were platinum-resistant and 15 patients were platinum-sensitive. The median survival durations were 10.6 and 19.9 months in the platinum-resistant and platinum-sensitive patients, respectively, and the prognosis was significantly better in the platinum-sensitive patients (p = .02).

Conclusions: Our findings suggest that the EXTREME regimen is useful as first-line therapy for R/M-SCCHN in platinum-sensitive patients.

Chinese abstract

背景：由铂剂、5-氟尿嘧啶和西妥昔单抗（EXTREME方案）组成的联合治疗被推崇用于治疗头颈部复发性或转移性鳞状细胞癌（R / M-SCCHN）。然而, 建议对耐铂剂的患者使用无铂方案作为一线治疗。还没有关于比较铂耐药和铂敏感患者的EXTREME方案结果的报道。

目的：检查作为R / M-SCCHN患者的一线治疗的EXTREME方案的结果和使用铂剂的历史, 并评估EXTREME方案结果在铂耐药患者和铂敏感患者之间是否不同。

材料和方法：该研究纳入了32名R / M-SCCHN患者, 他们接受了作为一线治疗的EXTREME方案。顺铂给药后6个月内复发或转移的患者被认为是铂耐药, 6个月内没有复发或转移的患者被认为是铂敏感。

结果：17名患者铂耐药, 15名患者铂敏感。铂耐药和铂敏感患者的中位生存期分别为10.6和19.9个月, 铂敏感患者的预后明显更好（p = .02）。

结论：我们的研究结果表明, EXTREME方案可用作铂敏感患者R / M-SCCHN的一线治疗。

Disclosure statement

No potential conflict of interest was reported by the authors.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 226.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.